These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11724656)

  • 1. Calculation of coronary risk in Type II diabetes.
    Durrington P
    Clin Sci (Lond); 2001 Dec; 101(6):681-2. PubMed ID: 11724656
    [No Abstract]   [Full Text] [Related]  

  • 2. Framingham risk equations underestimate coronary heart disease risk in diabetes.
    Stevens RJ; Coleman RL; Holman RR
    Diabet Med; 2005 Feb; 22(2):228. PubMed ID: 15660747
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk factors of macrovascular disease in diabetes mellitus.
    Jarrett RJ
    Horm Metab Res Suppl; 1985; 15():1-3. PubMed ID: 3865876
    [No Abstract]   [Full Text] [Related]  

  • 4. [Risk factors of microangiopathy in patients with non-insulin dependent diabetes mellitus].
    Czech A; Szczeklik Z; Przybyś W
    Pol Tyg Lek; 1996 Jan; 51(1-5):35-6. PubMed ID: 8754299
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk factors for macrovascular disease in type 2 diabetes. Classic lipid abnormalities.
    Steiner G
    Diabetes Care; 1999 Apr; 22 Suppl 3():C6-9. PubMed ID: 10189556
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors predicting the development of metabolic syndrome and type II diabetes against a background of hypertension.
    Lim HS; Lip GY; Beevers DG; Blann AD
    Eur J Clin Invest; 2005 May; 35(5):324-9. PubMed ID: 15860044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diabetes and coronary heart disease frequently appear together. New guidelines regulate therapy and prevention].
    MMW Fortschr Med; 2006 Oct; 148(41):10-1. PubMed ID: 17190248
    [No Abstract]   [Full Text] [Related]  

  • 8. [Role of endothelin I and angiotensin II in type 2 diabetics with coronary disease].
    Mundo-Sagardía J; Altieri P; Banch H; González R; Escobales N; Crespo M; Rodríguez-Orengo J; Cardona F; Torrado J
    Bol Asoc Med P R; 2003; 95(5):45-50. PubMed ID: 15008361
    [No Abstract]   [Full Text] [Related]  

  • 9. [Identification and prevention of vascular risk. Significance of metformin].
    Isnard F; André P
    Journ Annu Diabetol Hotel Dieu; 1990; ():311-23. PubMed ID: 2195214
    [No Abstract]   [Full Text] [Related]  

  • 10. Coronary artery disease and cerebrovascular disease prevention in diabetes mellitus: early identification and aggressive modification of risk factors.
    Hennessey JV; Westrick E
    Med Health R I; 1998 Nov; 81(11):350-2. PubMed ID: 15580789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence suggests diabetes outcomes linked to homocysteine.
    Clement L
    Nephrol News Issues; 2003 Dec; 17(13):16-7. PubMed ID: 14694857
    [No Abstract]   [Full Text] [Related]  

  • 12. Restenosis in diabetic patients: is hyperinsulinemia the culprit?
    Aronson D
    Circulation; 1996 Dec; 94(11):3003-5. PubMed ID: 8941148
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy.
    Brazionis L; Rowley K; Jenkins A; Itsiopoulos C; O'Dea K
    Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):786-91. PubMed ID: 18239151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.
    Cardiovasc J Afr; 2008; 19(3):171-2. PubMed ID: 18568186
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetes as a risk factor for coronary disease.
    Megarry S; Sapsford R; Hall A
    Practitioner; 1996 Jul; 240(1564):454-7. PubMed ID: 8801547
    [No Abstract]   [Full Text] [Related]  

  • 16. Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes.
    Byrne CD
    Diabetes Obes Metab; 2004 Jul; 6(4):308-9. PubMed ID: 15171756
    [No Abstract]   [Full Text] [Related]  

  • 17. Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate.
    Evans M; McEwan P; Peters JR; Currie CJ
    Diabetes Obes Metab; 2004 Jul; 6(4):299-307. PubMed ID: 15171755
    [No Abstract]   [Full Text] [Related]  

  • 18. Lipoprotein (a): role in diabetes and its vascular complications.
    Mohan A; Srinivasan V; Deepa R; Mohan V
    J Assoc Physicians India; 2001 Nov; 49():1100-5. PubMed ID: 11868866
    [No Abstract]   [Full Text] [Related]  

  • 19. [Macroangiopathy in diabetes mellitus].
    Janka HU
    Med Welt; 1983 Feb; 34(5):153-7. PubMed ID: 6843340
    [No Abstract]   [Full Text] [Related]  

  • 20. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location.
    Avogaro A; Giorda C; Maggini M; Mannucci E; Raschetti R; Lombardo F; Spila-Alegiani S; Turco S; Velussi M; Ferrannini E;
    Diabetes Care; 2007 May; 30(5):1241-7. PubMed ID: 17290034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.